China Pharma (NYSE:CPHI) Trading Down 3.1% – What’s Next?

China Pharma Holdings, Inc. (NYSE:CPHI) shares were down 3.1% during trading on Monday . The stock traded as low as $0.73 and last traded at $0.7470. Approximately 56,938 shares changed hands during mid-day trading, a decline of 68% from the average daily volume of 177,620 shares. The stock had previously closed at $0.7711.

China Pharma Stock Performance

The company has a market cap of $25.93 million, a price-to-earnings ratio of -1.16 and a beta of 1.15. The company has a current ratio of 0.79, a quick ratio of 0.26 and a debt-to-equity ratio of 0.22. The stock’s 50 day moving average price is $0.72 and its 200 day moving average price is $0.87.

Hedge Funds Weigh In On China Pharma

A hedge fund recently raised its position in China Pharma stock. Citadel Advisors LLC lifted its position in shares of China Pharma Holdings, Inc. (NYSE:CPHI) by 31.9% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 30,426 shares of the company’s stock after buying an additional 7,356 shares during the period. Citadel Advisors LLC owned approximately 0.93% of China Pharma worth $59,000 as of its most recent SEC filing.

China Pharma Company Profile

China Pharma Holdings, Inc develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People’s Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension.